Beckley Psytech Commences Phase 2a Trial for Treatment-Resistant Depression
Beckley Psytech is a clinical-stage biotechnology company focused on improving the lives of individuals living with neuropsychiatric disorders through the development of psychedelic drugs. In its latest press release, the company revealed that it has administered a new intranasal psychedelic using an FDA-approved delivery device to a patient with treatment-resistant depression during a phase 2a trial. The objective of the phase 2 trial is to assess the effectiveness, safety and pharmacokinetics of the company’s BPL-003 formulation when administered together with psychological support, to patients experiencing moderate to severe symptoms of treatment-resistant depression. BPL-003 is a synthetic formulation of the 5-MeO-DMT…






